TGF-β1 is a potent inducer of EMT in cancer, and treatment of hepatocellular carcinoma cell lines with TGF-β1 enhanced EMT acquisition via a GLI-SNAI1 dependent mechanism, which can be reversed by GLI1 knockdown. This evidence concerns the gene GLI1 and hepatocellular carcinoma.